SEC Form 4 · accession 0001193125-26-266277
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sumit Aggarwal
Officer — President and CEO · Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.65 | Jun 10, 2026 | A | 328,833 | A | — | Sep 19, 2035 | Common Stock | 328,833 | 328,833 | D |
Explanation of responses
- F1The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date.